Vaso Swings to Q2 Profit as Revenue Climbs 8.3% to $11.2M
VASO has more than doubled off its 52-week low of $0.105.
Summary
Vaso reported Q2 2026 net income of $542K, reversing a $197K loss a year ago, on revenue of $20.9M. Gross profit rose 11.3% to $13.1M, and operating cash flow for H1 was $4.8M. The company also disclosed deferred revenue of $41.5M, up 8.9% year-over-year. This follows the July 31 sale of NetWolves for $14.5M, which provided liquidity and is now classified as a discontinued operation. The results show improved profitability after divesting healthcare IT and network services, with professional sales services revenue up 20%.
At the time of this announcement, VASO was trading at $0.26 on OTC in the Life Sciences sector, with a market capitalization of approximately $45.8M. The 52-week trading range was $0.11 to $0.28. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.